Eli Lilly’s decision to acquire Centessa Pharmaceuticals for $7.8 billion in total consideration, announced in March 2026, is a clear statement of strategic intent. The Indianapolis pharma giant — already managing one of the most commercially successful pipelines in industry history through its GLP-1 receptor agonist franchise — is using its balance sheet to build a durable CNS presence, and Centessa’s orexin receptor programme is the centrepiece of the rationale.
Centessa’s lead CNS asset targets excessive daytime sleepiness (EDS), a condition characterised by an inability to maintain wakefulness during normal daytime hours, with pathophysiology tied directly to deficient orexin-A and orexin-B signalling in the hypothalamus. The orexin neuropeptide system regulates sleep-wake transitions, and loss of orexin-producing neurons is the defining lesion of narcolepsy type 1. Centessa’s orexin receptor agonist programme is aimed at pharmacologically restoring the signalling deficit rather than suppressing downstream symptoms.
This is not Lilly’s first move in orexin pharmacology, but it is by far the largest. The appetite for orexin-targeted programmes has intensified across the sector since the commercial success of suvorexant (Belsomra) and lemborexant (Dayvigo) as orexin receptor antagonists for insomnia demonstrated that the pathway is druggable in both directions and commercially viable. Agonism, however, is technically more demanding and carries a meaningfully different safety profile consideration, which is why competitive entry has been slower.
The $7.8 billion figure encompasses upfront and contingent value considerations and reflects the risk-adjusted valuation of a programme with Phase 2 clinical data but substantial Phase 3 work remaining. Lilly’s acquisition playbook has been consistent: buy assets with de-risked mechanisms, validated patient populations, and identifiable regulatory pathways, then leverage scale to execute late-stage trials at speed.
Centessa was also developing assets in additional neurological and rare disease indications, including a programme in sickle cell disease, but the EDS and narcolepsy pipeline was the evident strategic driver. Lilly’s CNS commercial infrastructure, physician relationships in sleep medicine and neurology, and global regulatory capabilities represent genuine operational synergies that a smaller company would struggle to replicate independently.
The broader context matters. Total biopharma M&A exceeded $106 billion in the first half of 2026, with licensing deal value reaching $77.3 billion in Q1 alone. Upfront cash represented only 6% of total licensing deal value, indicating that buyers and sellers are increasingly sharing risk through structured milestone payments. Lilly’s Centessa deal fits the larger pattern precisely: strategic asset, structured consideration, long runway to commercialisation.
For neuroscience-focused investors and clinical-stage companies developing CNS assets, the transaction reinforces that large-cap appetite for validated neurological mechanisms — particularly in sleep, cognition, and neurodegeneration — remains strong through mid-2026.
